U.S. markets closed
  • S&P Futures

    3,897.25
    -19.00 (-0.49%)
     
  • Dow Futures

    31,342.00
    -145.00 (-0.46%)
     
  • Nasdaq Futures

    12,077.25
    -63.25 (-0.52%)
     
  • Russell 2000 Futures

    1,752.50
    -9.20 (-0.52%)
     
  • Crude Oil

    105.63
    -1.99 (-1.85%)
     
  • Gold

    1,831.90
    +1.60 (+0.09%)
     
  • Silver

    21.13
    +0.00 (+0.02%)
     
  • EUR/USD

    1.0570
    +0.0011 (+0.11%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • Vix

    27.23
    -1.82 (-6.27%)
     
  • GBP/USD

    1.2288
    +0.0018 (+0.14%)
     
  • USD/JPY

    134.9720
    -0.1980 (-0.15%)
     
  • BTC-USD

    21,055.66
    -373.89 (-1.74%)
     
  • CMC Crypto 200

    458.26
    +4.36 (+0.96%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,760.96
    +268.99 (+1.02%)
     

Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Citi 15th Annual BioPharma Virtual Conference on Thursday, September 10 at 2:25 p.m. ET.

A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation.

About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts for Arvinas

Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com

Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com